Let's focus on what we can do!

By Disabled People for Disabled People

  • Home
  • >
  • Latest Headlines
  • >
  • #ACTRIMS2019 – Botox for Spasticity Earns Praise in ASPIRE Follow-up – Multiple Sclerosis News Today

#ACTRIMS2019 – Botox for Spasticity Earns Praise in ASPIRE Follow-up – Multiple Sclerosis News Today

Wednesday, 6 March, 2019

#ACTRIMS2019 – Botox for Spasticity Earns Praise in ASPIRE Follow-up – Multiple Sclerosis News Today

[responsivevoice_button voice="UK English Female" buttontext="Listen to Post”]

Patients with a range of diseases and disorders, including multiple sclerosis (MS), report high satisfaction with botulinum toxin — also known as Botox (onabotulinumtoxinA) — as a treatment for spasticity, results from the ASPIRE clinical trial show.

The data were presented last week by Daniel S. Bandari, MD, from the MS Center of California & Research Group at the Hoag Neurosciences Institute, at the 4th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum in Dallas, Texas. His poster was titled “Individualized OnabotulinumtoxinA Treatment for Spasticity in Multiple Sclerosis Resulted in High Patient and Clinician Satisfaction: The Aspire Study.”

Botox is approved by the U.S. Food and Drug Administration (FDA) to treat muscle spasms, spasticity, and bladder symptoms in patients with a spectrum of diseases, including MS. It is estimated that six to nine of every 10 MS patients experience spasticity at some point.

.
In collaboration with developer Allergan, an international team of researchers examined real-world data on the effectiveness of Botox to treat spasticity in a study called ASPIRE (NCT01930786). Researchers also assessed both patient and clinician satisfaction with the treatment.

The ASPIRE trial is a prospective, international, multicenter, observational study in centers across North America, Europe, and Asia, that examined 730 adult patients (average age 53.6 years) with spasticity symptoms. In this patient group, the most common diseases were stroke (56%), followed by MS (16%).

Of the initial patients, 397 (54%) completed a two-year follow-up period.

Researchers observed a wide range of injections in upper and lower limbs. Anatomical location and electromyogram (EMG) localization were the most frequently used injection guiding methods in upper and lower limbs, respectively.

Read more at: https://multiplesclerosisnewstoday.com/2019/03/05/actrims2019-botox-spasticity-earns-praise-aspire-follow-up/

Categories :
  • Latest Headlines
  • Multiple Sclerosis
Socials :

Recent posts